ENLV Enlivex Therapeutics Ltd
Company Analysis
Latest News
Enlivex Therapeutics Ltd Q2 2026 Earnings Preview: What Analysts Expect on September 04, 2026
Enlivex Therapeutics is expected to report a Q2 2026 loss of $0.31 per share on $0.00 in revenue, with the stock currently trading at $1.28 against an...
🔴 Enlivex Therapeutics is trading 6.2% down today on continued fallout from its dilutive equity offering
Enlivex Therapeutics is trading 6.2% down at $1.98 today as shares continue to digest the impact of last week's dilutive equity offering and related SEC...
🔴 Enlivex Therapeutics is trading 5.1% down today following an $80 analyst price target hike and a $400 million dilutive offering
Enlivex Therapeutics is trading 5.1% down today at $2.06 as the stock experiences sharp volatility following a massive analyst price target hike and...
🟢 Enlivex Therapeutics is trading 6% up today following a massive analyst price target hike
Enlivex Therapeutics is trading at $2.30, up 6% today as the stock rebounds from a dilution-driven selloff and reacts to a significant analyst price target...
🔴 Enlivex Therapeutics is trading 6% down today despite H.C. Wainwright raising its price target to $80
• Enlivex Therapeutics is trading at $2.04 (5.99% down) in after-hours sessions, retracing a portion of its sharp rebound from last week’s dilution-driven...
🟢 Enlivex Therapeutics is trading 10.3% up today as it rebounds from a sharp dilution-driven selloff
Enlivex Therapeutics is trading 10.3% up today at $2.15 as buyers return following a sharp dilution-driven drop tied to its recent $400 million crypto-linked...
🟢 Enlivex Therapeutics is trading 7.7% up today as investors reverse sharp post-financing selloff
Enlivex Therapeutics is trading 7.7% up today at $2.10 as investors partially reverse a sharp selloff triggered by a recent dilutive financing deal. • The...
🔴 Enlivex Therapeutics is trading 7.2% down today as market digests dilutive $400M crypto-linked financing
Enlivex Therapeutics is trading 7.2% down today at $1.81 as the market continues to digest a highly dilutive, crypto-linked $400 million private placement...
🟢 Enlivex Therapeutics is trading 5.1% up today as investors reassess recent dilution-driven selloff
Enlivex Therapeutics is trading at $2.05 (5.1% up) in pre-market as investors reassess the stock following a sharp two-day selloff triggered by a surprise $400...
🔴 Enlivex Therapeutics is trading 12.1% down today as crypto-funded placement fuels dilution concerns
Enlivex Therapeutics is trading 12.1% down at $1.98 today as investors react to a $400 million private placement funded with crypto tokens. • The selloff,...
🔴 Enlivex Therapeutics is trading 5.9% down today on dilution fears from crypto-funded placement
Enlivex Therapeutics is trading 5.9% down today at $2.05 as the market continues to react to its recently announced $400 million private placement funded with...
🔴 Enlivex Therapeutics is trading 5.8% down today as market digests $400M crypto-funded placement
Enlivex Therapeutics is trading at $2.11 (down 5.8%) as the market continues to digest yesterday’s surprise $400 million private placement paid in crypto...
Enlivex Lands a $400 Million Deal Paid in Crypto Tokens — But Can a Micro-Cap Biotech Really Absorb That Kind of Money
Shares of Enlivex shifted sharply as the Israeli biotech-turned-crypto-treasury company unveiled a $400 million private placement with a single unnamed...
🟢 Enlivex Therapeutics is trading 8% up today after $400M private placement deal at a premium price
Enlivex Therapeutics is trading at $2.42 (8% up) in pre-market following a $400 million private placement agreement with a single institutional investor. •...
Enlivex Therapeutics secures $400 million, targeting digital asset treasury strategy
Enlivex Therapeutics signed a $400 million private placement agreement with a single institutional investor. The deal prices shares at a premium to the July...